Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2013 by University of Arizona
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bruce Kaplan, University of Arizona Identifier:
First received: May 29, 2013
Last updated: June 7, 2013
Last verified: June 2013
This study is being conducted to determine if belatacept is an appropriate alternative immunosuppressive medication (reducing the immune system's effect) when a kidney transplant patient develops new onset diabetes after transplant (NODAT). Patients who are diagnosed with NODAT will be approached with the opportunity to participate in this study. If they agree to participate, they will be randomized one-to-one (like a coin flip) to the study arm (belatacept) or the control arm (their current medication regimen). If a patient is randomized to the study arm, they will be tapered off of their current regimen when they have started receiving their monthly belatacept infusions. The control arm will mean the patient will continue their current, standard of care medications, but following the tacrolimus trough levels indicated within the study protocol. Different laboratory tests (i.e. fasting blood glucose) will be measured during the study to monitor the progression of NODAT in all patients.

Condition Intervention Phase
New Onset Diabetes After Transplant
Kidney Transplantation
Drug: Belatacept
Drug: Tacrolimus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Open-Label, Randomized Comparison of NODAT in Renal Transplant Patients Receiving a Nulojix (Belatacept) Regimen Versus Standard Therapy Immunosuppression

Resource links provided by NLM:

Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Increased insulin sensitivity [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Increase in insulin sensitivity (HOMA-S) as calculated below:

    FIRI = fasting plasma insulin level

    FPG = fasting plasma glucose level

    HOMA-S (insulin sensitivity) is calculated as 22.5 / (FIRI * FPG)

  • Decreased insulin resistance [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Decreased insulin resistance (HOMA-IR) as measured below:

    FIRI = fasting plasma insulin level

    FPG = fasting plasma glucose level

    HOMA IR (insulin resistance) is calculated as (FIRI * FPG) / 22.5

Estimated Enrollment: 32
Study Start Date: August 2013
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Belatacept and CellCept
Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
Drug: Belatacept
Other Name: Nulojix
Active Comparator: Tacrolimus and CellCept
Tacrolimus and CellCept taken twice daily based on patient response.
Drug: Tacrolimus
Standard administration of tacrolimus
Other Name: Prograf


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent must be given by patient.
  • Adult patients between age 18 and 65
  • Thymoglobulin induction at the time of transplant
  • Patient must be Epstein-Barr Virus seropositive

Exclusion Criteria:

  • Patient who received an blood type incompatible transplant, or with T-cell or B-cell positive crossmatch
  • Patients with Hepatitis B, Hepatitis C, HIV or a clinically significant systemic infection within 30 days prior to transplant
  • History of stroke, severe cardiac disease or cardiac failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01875224

Contact: Bruce Kaplan, MD 520-626-6371
Contact: Rochelle Byrne, RN 520-626-9603

United States, Arizona
University of Arizona Not yet recruiting
Tucson, Arizona, United States, 85724
Contact: Rochelle Byrne, RN    520-626-9603   
Principal Investigator: Bruce Kaplan, MD         
Sponsors and Collaborators
University of Arizona
Bristol-Myers Squibb
Principal Investigator: Bruce Kaplan, MD University of Arizona
  More Information

Responsible Party: Bruce Kaplan, Chief of Abdominal Transplantation, University of Arizona Identifier: NCT01875224     History of Changes
Other Study ID Numbers: IM103-303 
Study First Received: May 29, 2013
Last Updated: June 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arizona:
kidney transplant
diabetes after transplant

Additional relevant MeSH terms:
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on May 01, 2016